about
Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson's DiseaseBench-to-bedside translation of magnetic nanoparticlesQuantum dots as a platform for nanoparticle drug delivery vehicle designGenetically modified mesenchymal stromal cells in cancer therapyTailored carbon nanotubes for tissue engineering applicationsStudy on performance of magnetic fluorescent nanoparticles as gene carrier and location in pig kidney cells.Cationic lipid-coated PEI/DNA polyplexes with improved efficiency and reduced cytotoxicity for gene delivery into mesenchymal stem cells.Polymeric Materials for Gene Delivery and DNA VaccinationLipophilic peptides for gene delivery.A new helper phospholipid for gene delivery.Engineering clustered ligand binding into nonviral vectors: alphavbeta3 targeting as an example.Intracellular mRNA regulation with self-assembled locked nucleic acid polymer nanoparticlesMultifunctional Poly(amine-co-ester-co-ortho ester) for Efficient and Safe Gene Delivery.Carbohydrate polymers for nonviral nucleic acid delivery.Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells.Cholesterol-peptide hybrids to form liposome-like vesicles for gene delivery.Highly effective gene transfection in vivo by alkylated polyethylenimine.Clustered Arg-Gly-Asp peptides enhances tumor targeting of nonviral vectors.Smart polymeric nanoparticles for cancer gene delivery.Examination of structure-activity relationship of viologen-based dendrimers as CXCR4 antagonists and gene carriers.Embryo-maternal communication in bovine - strategies for deciphering a complex cross-talk.Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells.In vitro study of partially hydrolyzed poly(2-ethyl-2-oxazolines) as materials for biomedical applications.Sequence Programmable Peptoid Polymers for Diverse Materials Applications.CaCO₃/CaIP₆ composite nanoparticles effectively deliver AKT1 small interfering RNA to inhibit human breast cancer growth.The effect of glycosaminoglycan content on polyethylenimine-based gene delivery within three-dimensional collagen-GAG scaffolds.In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivoDeveloping a Novel Gene-Delivery Vector System Using the Recombinant Fusion Protein of Pseudomonas Exotoxin A and Hyperthermophilic Archaeal Histone HPhA.Effects of the incorporation of a hydrophobic middle block into a PEG-polycation diblock copolymer on the physicochemical and cell interaction properties of the polymer-DNA complexes.The target discovery process.Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvantNovel siRNA formulation to effectively knockdown mutant p53 in osteosarcomaTransfection efficiency of pORF lacZ plasmid lipopolyplex to hepatocytes and hepatoma cells.Critical Length of PEG Grafts on lPEI/DNA Nanoparticles for Efficient in Vivo Delivery.RALA-mediated delivery of FKBPL nucleic acid therapeuticsPeptide-functionalized poly(ethylene glycol) star polymers: DNA delivery vehicles with multivalent molecular architectureLipid bilayer curvature and pore formation induced by charged linear polymers and dendrimers: the effect of molecular shape.A nanoparticle formulation that selectively transfects metastatic tumors in miceEnhanced gene delivery using disulfide-crosslinked low molecular weight polyethylenimine with listeriolysin o-polyethylenimine disulfide conjugate
P2860
Q26752578-6D90AC03-B041-4D9A-A896-19CA67AD81EFQ26850547-74049EB7-A6AD-43F9-A324-F752362FEFF0Q26996556-73469D2A-96C6-40CE-89C9-7D2DC38E7613Q28071840-356B28BB-AF68-4C41-A380-5EBE12011370Q28389412-A9688E4E-192B-46D6-BD6D-8D3321075F3AQ30394025-32AC79B0-B1F0-4124-9658-FABD8909A0E9Q30560846-0933D15D-36D0-485F-83C1-1A235DA998A9Q33565296-A06C3565-2B3B-420B-AB81-14B4211C7AE7Q33635670-56EE2281-10CC-4E50-8D62-D072A26DA651Q33635691-3D6890F8-215C-4ADF-B9DC-83A2E7337432Q33713483-9B7654E9-7AD9-4431-A7EC-57EC53F511C0Q33715958-673D460B-2CB5-4ABE-B4FF-DE8F81A83A2FQ33822106-1F9336AF-E92C-4418-86F1-4DBAF84C63A4Q33897565-04B07F91-F2BD-4A9C-8AD0-9048E6EB998FQ33935474-1F0B12CA-924B-4D65-82D2-62204FC81A94Q34378581-FA422A85-4E6F-4D9D-A70F-B59658B97410Q34575422-8352C25E-290F-4435-B1B0-C0B1915769B9Q34730046-1995E323-0A8D-44AD-837B-EE3B14B4D0AAQ34812125-76C1718F-F31F-4C4B-97D1-063485D0FA0AQ35057532-CB2D7CD1-CA62-4029-BCFF-E35EF559B004Q35167546-95BD2250-E429-4B6C-B5D0-ADCE28067E8BQ35187580-CA8F274D-D1CC-4016-9135-0693D3672BC2Q35234161-46FE914C-5C79-4A20-9FEC-A70F1F694697Q35580002-CC6B76E7-A6CC-410E-819E-E1EC9C439EA4Q35597920-CB124B3C-B54D-43EA-A291-841FF2F0B4FEQ35690245-A262B9C1-4309-490B-872F-C85680B915CCQ35748080-A4C33DC9-7C2F-4573-B7D0-C1BC5796D883Q35802123-6531AAB2-05D9-4CFD-8BC0-EDEFF71DE7C7Q35837728-126DD38B-A3CA-4F36-B0E1-146B86FF62DCQ35919062-D319F5BC-673C-456A-BEF9-8E8392C6A366Q36059506-DE8A5017-ED2B-41B1-98B7-003909616B32Q36085370-CE23A4D2-6130-4738-A581-6D2467348446Q36411432-808547A7-FCF7-4AAE-80EF-7235F8E70B7FQ36474300-3A70F64B-7022-4B92-9794-FF9668962E2FQ36793350-277BC058-2CE1-4858-8469-245DC4DB4868Q37013400-2256B9E1-3A42-4045-83A0-035DDA54A125Q37115553-5454407E-F79C-4955-A5A6-11D56FB12933Q37131924-434FD2F6-F457-465C-A925-A0BFEB3A60FCQ37157373-E9645B3F-DFB7-4611-96AC-C9BB57B065A3Q37217780-05FF5EB7-6922-434B-8151-354CEC83FAA1
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Non-viral gene delivery systems.
@ast
Non-viral gene delivery systems.
@en
Non-viral gene delivery systems.
@nl
type
label
Non-viral gene delivery systems.
@ast
Non-viral gene delivery systems.
@en
Non-viral gene delivery systems.
@nl
prefLabel
Non-viral gene delivery systems.
@ast
Non-viral gene delivery systems.
@en
Non-viral gene delivery systems.
@nl
P1476
Non-viral gene delivery systems.
@en
P2093
Mark E Davis
P304
P356
10.1016/S0958-1669(02)00294-X
P577
2002-04-01T00:00:00Z